Indoco Remedies Q3 FY26 Earnings Call Transcript Released
Indoco Remedies' Q3 FY26 earnings call transcript reveals consolidated net revenues of INR4,343 million, up 7.9% YoY. International formulations grew 26.2%, and API business rose 24%. The company launched new OTC products in India and aims for over 20% revenue growth in Europe in the coming years. Total debt is around INR900 crores.
The announcement is a transcript of an earnings call, providing detailed financial and operational updates. While there are positive growth indicators and future outlooks, the impact is considered medium as it doesn't involve a new major strategic decision, acquisition, or significant financial event like fundraising or dividend declaration. It serves as an update on ongoing performance and strategy.
The company reported year-on-year revenue growth, improved EBITDA margins, and positive performance in key segments like international formulations and APIs. Management expressed confidence in future growth, particularly in Europe and the US markets, and highlighted successful new product launches and regulatory audit clearances.
Indoco Remedies Limited has released the transcript of its Earnings Conference Call held on February 3rd, 2026, discussing the Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine Months Ended December 31st, 2025. The call, hosted by Nirmal Bang Institutional Equities, featured insights from Managing Director Ms. Aditi Panandikar, Joint MD Mr. Sundeep V. Bambolkar, and CFO Mr. Pramod Ghorpade.
Ms. Panandikar highlighted a better performance in Q3 FY26, particularly in export divisions and APIs, with subsidiaries like FPP in the U.S. and Warren Remedies showing improvement. The company launched two new products in the OTC business in India: Sensodent DSP and Sensodent DPC. While the domestic business was flat due to challenges in acute therapies, Indoco jumped to 21st rank in the prescription audit with 10.86 crore prescriptions on a MAT basis. The Patalganga API site received EIR for a USFDA audit with zero 483s, and the company received the Most Preferred Workplace Award for '25-'26.
Financially, consolidated net revenues for Q3 FY26 were INR4,343 million, a 7.9% increase year-on-year. Consolidated EBITDA to sales improved to 7.3% (INR315 million) from 3% last year. International Formulation business grew by 26.2% to INR1,356 million, with regulatory markets up 25.9% and U.S. business up 21.6% to INR341 million. API business grew by 24% to INR344 million.
The management discussed challenges in Europe with some approvals being delayed, and provided updates on other expenses, noting approximately INR8-9 crores of non-recurring costs. They expressed confidence in improving margins and growing the European business to over 20% in revenues within a few years, potentially reaching INR400-500 crores by FY28-29. Warren Remedies saw over 43% growth in the quarter, driven by OTC and OTX segments. The API business is expected to see consolidation in FY27 with validation batches, with potential for margin improvement once new capacities at the Auric site are qualified by USFDA or EU.
The company's total debt stands at approximately INR900 crores (INR700 crores in the main business and INR200 crores in WRPL). Repayments are scheduled, and the company is focused on revenue growth, operational efficiencies, and reduced interest costs to manage debt. They are exploring possibilities to lower debt and are careful about further capital expenditure.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.